Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.05500.0000 (0.00%)
At close: 03:59PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0550
Open0.0600
Bid0.0500 x N/A
Ask0.0550 x N/A
Day's Range0.0550 - 0.0600
52 Week Range0.0500 - 0.3400
Volume201,067
Avg. Volume285,645
Market Cap23.263M
Beta (5Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-0.1100
Earnings DateApr 13, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TBP.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can

    • PR Newswire

      Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, held its annual general and special meeting (the "Meeting") of its holders of common shares (the "Shareholders") virtually on May 30, 2022. The Company is pleased to announce that all matters presented for approval at the Meeting were approved, except with respect to the proposed share consolidation of the issued and outstanding common shares of

    • PR Newswire

      Tetra Bio-Pharma Appoints Chief Financial Officer

      Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld, H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company's executive team, effective May 30, 2022.

    Advertisement
    Advertisement